MX2021007217A - Compuesto organico. - Google Patents

Compuesto organico.

Info

Publication number
MX2021007217A
MX2021007217A MX2021007217A MX2021007217A MX2021007217A MX 2021007217 A MX2021007217 A MX 2021007217A MX 2021007217 A MX2021007217 A MX 2021007217A MX 2021007217 A MX2021007217 A MX 2021007217A MX 2021007217 A MX2021007217 A MX 2021007217A
Authority
MX
Mexico
Prior art keywords
organic compound
involving
receptor
sert
carboline
Prior art date
Application number
MX2021007217A
Other languages
English (en)
Inventor
Peng Li
Qiang Zhang
Robert Davis
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2021007217A publication Critical patent/MX2021007217A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B5/00—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una gamma-carbolina fusionada con un heterociclo sustituido particular, en una forma libre, o de sal farmacéuticamente aceptable, y/o sustancialmente pura, tal y como se describe en el presente documento, a las composiciones farmacéuticas de la misma, y los métodos de uso en el tratamiento de las enfermedades que implican al receptor de 5-HT2A, al transportador de serotonina (SERT, por sus siglas en inglés), y/o a las vías que implican al sistema de señalización de los receptores de dopamina D1 y D2.
MX2021007217A 2018-12-17 2019-12-17 Compuesto organico. MX2021007217A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862780804P 2018-12-17 2018-12-17
PCT/US2019/066894 WO2020131899A1 (en) 2018-12-17 2019-12-17 Organic compound

Publications (1)

Publication Number Publication Date
MX2021007217A true MX2021007217A (es) 2021-07-15

Family

ID=71102816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007217A MX2021007217A (es) 2018-12-17 2019-12-17 Compuesto organico.

Country Status (11)

Country Link
US (1) US20220056030A1 (es)
EP (1) EP3898221A4 (es)
JP (1) JP7487204B2 (es)
KR (1) KR20210104785A (es)
CN (1) CN113423568A (es)
AU (1) AU2019403150A1 (es)
BR (1) BR112021011792A2 (es)
CA (1) CA3121635A1 (es)
IL (1) IL283961A (es)
MX (1) MX2021007217A (es)
WO (1) WO2020131899A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1370176A (zh) 1999-06-15 2002-09-18 布里斯托尔-迈尔斯斯奎布药品公司 取代的杂环稠合γ－咔啉
MX2018009158A (es) * 2016-01-26 2018-11-19 Intra Cellular Therapies Inc Compuestos organicos.
PL3407889T3 (pl) * 2016-03-25 2021-11-22 Intra-Cellular Therapies, Inc. Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego

Also Published As

Publication number Publication date
IL283961A (en) 2021-07-29
CA3121635A1 (en) 2020-06-25
CN113423568A (zh) 2021-09-21
BR112021011792A2 (pt) 2021-08-31
EP3898221A4 (en) 2022-09-14
US20220056030A1 (en) 2022-02-24
EP3898221A1 (en) 2021-10-27
AU2019403150A1 (en) 2021-07-08
WO2020131899A1 (en) 2020-06-25
JP7487204B2 (ja) 2024-05-20
KR20210104785A (ko) 2021-08-25
JP2022514264A (ja) 2022-02-10

Similar Documents

Publication Publication Date Title
MX2021010306A (es) Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso.
MX2021013564A (es) Gamma-carbolinas fusionadas con heterociclo deuterado.
MX2020000968A (es) Compuestos organicos.
MX2019007474A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
MX2016013046A (es) Compuestos organicos.
MX2020000967A (es) Compuestos organicos.
MX2012012277A (es) Compuestos organicos.
MX2014012374A (es) Compuestos organicos.
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
SG11201809859VA (en) Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
MX2020009929A (es) Compuestos organicos.
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
MX2020009928A (es) Compuestos organicos.
MX2016014946A (es) Derivados de carboxamida.
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
MX2021007217A (es) Compuesto organico.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MX2018008153A (es) Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, metodo para prepararlos y composición farmacéutica que los contiene.
JOP20200127A1 (ar) مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية
WO2023178113A3 (en) Organic compounds
MY189372A (en) Indole derivatives
PH12016502540A1 (en) Pharmaceutical dosage forms